MDT

86.81

-0.34%↓

A

115.29

+0.17%↑

VEEV

156.49

+3.32%↑

HQY

78.14

+0.03%↑

TLRY

6.47

-1.67%↓

MDT

86.81

-0.34%↓

A

115.29

+0.17%↑

VEEV

156.49

+3.32%↑

HQY

78.14

+0.03%↑

TLRY

6.47

-1.67%↓

MDT

86.81

-0.34%↓

A

115.29

+0.17%↑

VEEV

156.49

+3.32%↑

HQY

78.14

+0.03%↑

TLRY

6.47

-1.67%↓

MDT

86.81

-0.34%↓

A

115.29

+0.17%↑

VEEV

156.49

+3.32%↑

HQY

78.14

+0.03%↑

TLRY

6.47

-1.67%↓

MDT

86.81

-0.34%↓

A

115.29

+0.17%↑

VEEV

156.49

+3.32%↑

HQY

78.14

+0.03%↑

TLRY

6.47

-1.67%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

75.93 1.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.65

Max

77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+32.21% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.4B

12B

Ankstesnė atidarymo kaina

74.81

Ankstesnė uždarymo kaina

75.93

Naujienos nuotaikos

By Acuity

50%

50%

148 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-12 23:44; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

2026-04-12 23:38; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

2026-04-12 23:38; UTC

Rinkos pokalbiai

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

2026-04-12 23:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

2026-04-12 23:31; UTC

Rinkos pokalbiai

A2 Milk's Supply Issues Likely Temporary -- Market Talk

2026-04-12 23:09; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

2026-04-12 23:06; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-12 23:06; UTC

Rinkos pokalbiai

Australian Dollar Ripe for a Downward Correction -- Market Talk

2026-04-12 22:56; UTC

Svarbiausios naujienos

Spot Gold Falls 1.9% to $4,658.65 per Ounce

2026-04-12 22:54; UTC

Svarbiausios naujienos

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

2026-04-12 22:53; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

2026-04-12 22:51; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

2026-04-12 22:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

2026-04-12 22:37; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

2026-04-11 08:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-11 08:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-11 08:20; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-11 00:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Big Yachts, Big Bucks -- Barrons.com

2026-04-10 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026-04-10 21:01; UTC

Uždarbis

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026-04-10 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-10 20:31; UTC

Rinkos pokalbiai

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026-04-10 20:10; UTC

Įsigijimai, susijungimai, perėmimai

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026-04-10 19:15; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-10 19:15; UTC

Rinkos pokalbiai

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-10 19:08; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026-04-10 18:38; UTC

Rinkos pokalbiai

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

32.21% į viršų

12 mėnesių prognozė

Vidutinis 99.38 USD  32.21%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

12

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

148 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat